Background: Visfatin is a novel adipocytokine predominantly secreted from visceral fat and its blood shows insulin-mimetic effects which correlate with overweight, type 2 diabetes mellitus (T2DM) and inflammation. Overweight is an important component of metabolic syndrome. However, the relationship between visfatin levels and overweight is not yet clear. The aim of this study was to investigate the relationship of serum visfatin levels in overweight and apparently healthy subjects.
glucose and insulin levels, whereas plasma glucose levels was shown higher in mice heterozygous for visfatin deficiency compared to it in normal mice. 7, 8 Published data also suggest that visfatin had effects on lipid homeostasis similar to that of insulin and it is responsible for adipocyte proliferation, differentiation and triglyceride (TG) metabolism. 9 Based on these findings, circulating visfatin levels and its determinants have been investigated in a number of clinical studies 6, 10, 11, 12 that observed visfatin expression in visceral fats is increased in overweight subjects and plasma levels of visfatin associated to a great extent with amount of visceral fat than that of adipose tissues. Overweight and T2DM are emerging as central health problems worldwide. Rise in overweight is associated to a subsequent increase in risk of T2DM. The International Association for the Study of Obesity/International Obesity Taskforce analysis in the year 2010 estimates that approximately one billion adults are currently overweight (Body Mass Index [BMI] 25-29.9 Kg/m²), and a further 475 million adults are obese.
With an Asian-specific definition of obesity (BMI>28 Kg/m 2 ), global obesity prevalence in adults is estimated at>600 million. 13, 14 It has been reported that it is primarily central or visceral fat relatively than subcutaneous fat seen in the region of big buttocks and thighs which is responsible for unfavorable ramifications of overweight. 15 This feature has drawn particular attention by raising question about potential differences between visceral and subcutaneous fat. Reviewing above findings, it may be suggested that visfatin might serve as a new link between overweight and T2DM but in an outwardly inconsistent manner. Furthermore, observational studies examined association of visfatin with adiposity and differential regional fat distribution have shown great discrepancies in their findings and more study is needed to establish the role of visfatin in visceral overweight. This crosssectional comparative study was carried out in a private multi purpose specialized hospital which is situated in central Dhaka, from July 2007 and July 2008. A recent study in Bangladeshi population observed elevated plasma visfatin level in T2DM. 16 Aim of this study was to examine the relationship of visfatin and overweight by analyzing biochemical and anthropometric parameters in overweight individuals and apparently normal healthy adults.
Mathodology

Informed consent
All protocols used for the recruitment of patients / healthy subjects and the collection of blood samples was reviewed and approved by the appropriate competent committee.
Study populations Healthy individuals, Group-I (Gp-I)
Forty two age-(41 6 years, Mean±SD), sex-and BMI-matched apparently healthy adult volunteers who had no family history of T2DM were recruited as Controls.
Overweight subjects Group-II (Gp-II)
Fifty adults, age 43 6 (Mean±SD) years who attended our Out-Patients Clinic seeking consultation for simple overweight were investigated in this study. All those 50 individuals were confirmed by clinical and laboratory examination that they are free from T2DM or any other known diseases. There was no specific predilection for race, religion and socioeconomic status.
Anthropometric measurements
Anthropometric measurements including HT in meter (m), BW in kilograms (kg), WC in centimeter (cm), HC in cm, were measured by applying appropriate standard techniques. BMI of the subjects were calculated using international standard formula, BMI= Weight (Kg)/ [Height (m)] 2 . Simple overweight was defined when an overweight individual shows BMI 17 between 25-29 Kg/m 2 . Percentage BFM was measured by Omron Body Fat Monitor (Omron Corporation, Japan) following manufacturer instructions.
Biochemical Parameters
Serum Glucose and Lipid profiles were measured by enzymatic colorimetric method (Randox Laboratories, UK) and estimation was carried out in an autoanalyzer (Hitachi 704). Insulin and Visfatin were estimated by ELISA (kits from Linco Research, and ALPCO diagnostics, USA).
Satistical Analysis
Comparisons of anthropometric and biochemical characteristics between two groups were analyzed using unpaired student's 't' tests. Pearson's correlation analysis were performed to investigate the possible associations between serum concentration of visfatin with anthropometric parameters. The SPSS version 10.0 was used for computing all analyzes.
Results
Age (M±SD) in Gp-I and Gp-II was 41 6 and 43 6 years respectively as shown in Table 1 (Table 2) . No difference also was observed between Gp-I, 11.2±4.1 (M±SD) and Gp-II 11.6±1.3 (M±SD) for fasting insulin levels (µU/ml) as shown in Table 3 . Fasting serum visfatin (ng/ml) value in Gp-I and Gp-II was 4.2 4.0 and 7.4 4.2 respectively which was significantly higher (p=0.000) in Gp-II as compared to Gp-I (Table 2) . Interestingly, levels of visfatin did not show any significant correlation with fasting glucose, fasting serum insulin,WC, HC, % BFM, TG and Cholesterol.
Table-I: Shows comparison of mean values of
anthropometric parameters between Gp-I and Gp-II using unpaired students 't' tests of the study subjects n= number of subjects 
Discussion
Overweight specific adipocytokines increased levels could play a vital role in obese associated metabolic derangements. 18 Our study is intended to investigate serum levels of visfatin and its correlation to nondiabetic overweight individuals. The increasing prevalence of overweight around the globe is becoming an important public health concern in adulthood and presents various complications. Because visceral adipose tissue is considered as an important source of visfatin, studies on visfatin alterations in adults may be useful in understanding 21 observed visfatin level was significantly associated with total CHOL, TG, HDL-CHOL, and LDL-CHOL in simple re-regression analysis but not in multiple regression. However, this study shown no significant correlation between serum visfatin and total CHOL, TG, HDL-CHOL, LDL-CHOL levels. It is still indistinguishable whether visfatin influences lipid profile limits or vice versa. We propose that visfatin elevations are independent to glucose, insulin and insulin resistance, which indicate that elevated visfatin levels are related to other factors like visceral fat deposit and inflammation. Fahmida et al 16 reported that serum visfatin levels are independent and significantly associated with T2DM. Our report also is in consistent with earlier report who observed no correlation between visfatin levels and fasting plasma glucose. We like to hpothesize that visfatin is more plausibly to be a marker of overweight as a product of visceral fat cells rather than a new key in the pathogenesis of T2DM. The absence of a relationship with biochemical parameters suggest visfatin is independently regulated in overweight subjects. These findings are new in association with the role of visfatin on overweight. We wish to test this hypothesis in a well-designed large population study to clarify these divisive data on visfatin and uncover relationship of adipocytokines to overweight, insulin resistance T2DM and systemic metabolic syndromes.
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